Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2195-2200

  Hashimoto, K ^a   Yonemori, K ^a   Katsumata, N ^a   Shimizu, C ^a   Hirakawa, A ^b   Hirata, T ^a   Kouno, T ^a   Tamura, K ^a   Ando, M ^a   Fujiwara, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Breast cancer; Measurable disease; Prediction; Progression disease; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VALIDATION PROCESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 77958495871     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq213     Document Type: Article

References (12)

1. Rustin GJ, Timmers P, Nelstrop A et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006 24: 45-51.
2. Eagle K, Ledermann JA. Tumor markers in ovarian malignancies. Oncologist 1997; 2: 324-329.
3. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 2008; 53: 478-496.
4. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-278.
5. Molina R, Zanon G, Filella X et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-48.
6. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
7. Kim HS, Park YH, Park MJ et al. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 2009; 118: 89-97.
8. Katsumata N, Watanabe T, Minami H et al. Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol 2009; 20: 1210-1215.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
10. Yonemori K, Katsumata N, Noda A et al. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol 2008; 134: 1199-1206.
11. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.